About Us

---

In Jerzy's early years, he studied High Tech Electronics in Rzeszów, Poland,  graduating in 1984. He enrolled in the NCO air force school in Grudziadz, supervising flight safety and graduating two years later.  Building on his medical education from 1998 to 2000, he attended the Marco Polo School in Chicago, where he became state-licensed in bodywork.  He went on to further his education in sports and medical therapy, along with additional related disciplines. In the early 2000's, he created distribution channels in the U.S. and EU for medical and cosmetic devices.  Over the past 25 years, Jerzy and his wife acquired several dental and medical buildings, which he managed while continuing to treat patients.   In 2015, after experiencing multiple episodes of fluoroquinolone-induced health crises that led to a cascade of severe complications, Jerzy was forced to leave his profession and sell many of his clinics. Determined to find answers, he began independent research into fluoroquinolone toxicity and, together with Jane Crosby, founded the nonprofit organization, Fluoroquinolone Toxicity Study.   Engaging with scientists at home and abroad, they analyzed thousands of science publications on quinolones.  Seeing the dire need for research, the Foundation organized the first known individual in vitro tests for genomic and mitochondrial fluoroquinolone DNA adducts and in vivo study of over 50 fluoroquinolone damaged and disabled participants.  Jerzy believes that continued research will uncover critical answers and increase medical awareness of the dangers associated with fluoroquinolone toxicity.   

Damaged by Levaquin in 2009, Jane became a member of the Fluoroquinolone Toxicity Group in Facebook and in 2013 joined the team of administrators in several online support groups for Fluoroquinolone victims.  She has dedicated the last seven years continuing to help administrate these groups, faithfully remaining in touch with the communities’ needs.  She developed a friendship with Dr. Jay Cohen, author of the book How We Can Halt the Cipro and Levaquin Catastrophe; The Worst Medication Disaster in U.S. History.  Dr. Cohen published his book in time for a public hearing between the FDA and a group of severely damaged fluoroquinolone victims and commissioned Jane to deliver a signed copy to the head of a FDA advisory panel.  In 2015 she co-founded Fluoroquinolone Toxicity Study with Jerzy Tyszkowski.  In addition to arranging study parameters and participant selection for the Foundation's studies, Jane’s hope is to find effective treatments for patient recovery and advocate for justice on behalf of those whose livelihoods and health have been lost due to the adverse events of fluoroquinolone toxicity.

Sarah graduated from the University of Minnesota in 1989.  She found herself facing a  significant setback in 2013 when she was affected by fluoroquinolones  for the fifth time in her life.  The severity of her condition this time forced her to permanently leave the workforce and shift her focus entirely to her health.  Sarah joined the Foundation in 2018, driven by a strong desire to channel her energy into a meaningful cause with the potential to create lasting impact. With a professional background in tech startup operations and commercial real estate portfolio management, she brings a wealth of organizational and operational expertise to support our mission.  She is responsible for the Foundation’s  website, media platforms, written  communications, and collaborating with various stakeholders and  governmental bodies at both national and international levels.  Additionally, Sarah plays a key role with research study initiatives and planning.   In prior years, Sarah was instrumental in leading teams on successful California state propositions and now channels that same unwavering dedication and drive to improving the lives of those living and navigating the journey of antibiotic adverse effects. 

Beatrice Alexandra Golomb MD, PhD, is a highly respected researcher and advocate for individuals suffering from complex medical conditions, including Fluoroquinolone-Associated Disability (FQAD) and Gulf War illness. As the Director of the Golomb Research Group and a Professor of Medicine at the University of California, San Diego, she has dedicated her career to studying the biological mechanisms underlying these conditions, with a focus on oxidative stress, mitochondrial dysfunction, and the balance of treatment risks and benefits.  Dr. Golomb’s impressive academic background includes a BS in physics (summa cum laude) from the University of Southern California with both an MD and PhD in biology from UC San Diego. She has served as a primary care physician for veteran patients for over 15 years, bringing firsthand clinical experience to her research. Her groundbreaking studies on Gulf War illness, statins, placebos, and fluoroquinolones have earned international recognition, establishing Dr. Golomb as a leading researcher in the scientific community and a tireless advocate for those affected by fluoroquinolone toxicity and FQAD.  Throughout an accomplished career, she has been featured in major media, including The New York Times, The Wall Street Journal, and The Economist, with appearances on prominent network shows and news stations. Dr. Golomb has contributed to expert panels, served as a peer reviewer for major scientific journals, and provided briefings to National Academies groups. Additionally, she is also a distinguished lecturer, a featured presenter and book author. For those suffering from FQAD and related conditions, Dr. Golomb remains one of the most dedicated and outspoken researchers, continuously pushing for greater awareness, better treatments, and systemic changes in medical and pharmaceutical oversight.  

Dr. Robert Pietruszyński is a distinguished specialist in internal medicine, cardiology, and sports medicine, with a career spanning decades of clinical practice and research. A graduate of the prestigious Military Medical Academy in Łódź (1989), he currently serves at the University Clinical Hospital WAM in Łódź, where he has been instrumental in advancing vascular diagnostics and pioneering research in computed tomography angiography (CTA) of the heart and aorta. Beyond his clinical expertise, Dr. Pietruszyński has played a vital role in sports medicine as a team physician for the Polish Cycling Federation for multiple Olympic Games. His proficiency in echocardiography, exercise stress testing, and cardiopulmonary exercise testing (CPET) places him as an expert in evaluating physical performance and cardiovascular health. Dr. Pietruszyński is also deeply engaged in the study and treatment of Fluoroquinolone-Associated Disability (FQAD), focusing on the profound impact of oxidative stress, mitochondrial dysfunction, QT prolongation, and cardiovascular risks associated with fluoroquinolone toxicity. His notable research includes a 2020 publication in Archives of Medical Science, where he examined the potential of antioxidant therapy for FQAD patients. A widely published researcher, Dr. Pietruszyński has contributed extensively to the fields of cardiology, sports medicine, and fluoroquinolone toxicity, solidifying his reputation as a leader in both clinical practice and scientific inquiry.

Dr. Gustavson graduated with a Doctor of Medicine from the University of Texas Medical Branch, Galveston, in 1992. After a past immersed in various biological research projects and responsibility for several federal grant projects, he commenced his residency in Psychiatry at Good Samaritan Regional Medical Center and then general neurology with subspecialty and research fellowship at the UCLA School of Medicine. He is the recipient of numerous academic awards, including the John Douglas French Alzheimer’s Foundation Research Fellowship Award and named Diana Streisand Kind Fellow in August, 2003. With numerous publications on his research in scientific and academic journals, Dr. Gustavson has also extensively lectured to academic, clinical and educational institutions spanning the last 30 years.  Drawing from his personal experience with the adverse effects of fluoroquinolones, he incorporates this understanding into his work as a Behavioral Neurologist in private practice. 

As a graduate from UAMS College of Medicine in 2009, Dr. Beard did her residency in Family Medicine and chose to work in the ER treating patients for urgent and emergent conditions. She started her own primary care concierge practice in 2013 which morphed into a functional medicine practice treating diverse cases. In 2016 she also took on the position as Medical Director of Cardiac Rehab at the Arkansas Heart Hospital and obtained her Functional Medicine Certification in 2017.   Dr. Beard practices functional medicine at her clinic, dedicated to helping patients unlock their full health potential. She is passionate about increasing fluoroquinolone awareness by promoting shared education between those affected and the medical community, while actively working to reduce misinformation about these and other potentially harmful drugs. 

In 2019, Marco experienced a severe reaction to multiple courses of ciprofloxacin while pursuing his medical degree at the University of Zurich, Switzerland. This ordeal forced him to make significant adjustments to both his personal and professional life. After a partial recovery, he approached his university education with newfound determination – his purpose now was to educate as many healthcare professionals as possible about the dangers of fluoroquinolone toxicity.  Marco successfully completed his medical studies and graduated from the University of Zurich in 2024. Throughout his academic journey, he worked on a publication about fluoroquinolone-induced small fiber neuropathy and collaborated in ongoing research with Dr. Stefan Pieper, the author of "Fluoroquinolone-Associated Disability (FQAD): Pathogenesis, Diagnostics, Therapy, and Diagnostic Criteria." As a newly graduated physician, Marco continues to be an active member of FQAD Support, an organization dedicated to aiding individuals experiencing systemic adverse effects from fluoroquinolone antibiotics. He remains committed to raising awareness about fluoroquinolone toxicity among healthcare professionals and improving patient care in this area.

Contact: marco.karrer@hin.ch